• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

兰地洛尔用于重症监护中房颤的管理。

Landiolol for managing atrial fibrillation in intensive care.

作者信息

Rehberg Sebastian, Joannidis Michael, Whitehouse Tony, Morelli Andrea

机构信息

Department of Anaesthesiology, University Hospital of Greifswald, Greifswald, Germany.

Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria.

出版信息

Eur Heart J Suppl. 2018 Jan;20(Suppl A):A15-A18. doi: 10.1093/eurheartj/sux039. Epub 2018 Jan 8.

DOI:10.1093/eurheartj/sux039
PMID:30188960
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5909768/
Abstract

Landiolol is an injectable ultrashort acting beta-blocker with high beta1 selectivity indicated for heart rate control of atrial fibrillation in the emergency and critical care setting. Accordingly, landiolol is associated with a significantly reduced risk of arterial hypotension and negative inotropic effects. Based on this particular profile along with the clinical experience in Japan for more than a decade landiolol represents a promising agent for the management of elevated heart rate and atrial fibrillation in intensive care patients even with catecholamine requirements. This article provides a review and perspective of landiolol for heart rate control in intensive care patients based on the current literature.

摘要

兰地洛尔是一种注射用超短效β受体阻滞剂，具有高度的β1选择性，适用于急诊和重症监护环境下房颤的心率控制。因此，兰地洛尔与显著降低的动脉低血压风险和负性肌力作用相关。基于这一特殊特性以及在日本十多年的临床经验，兰地洛尔是一种有前景的药物，可用于治疗重症监护患者即使需要使用儿茶酚胺时的心率升高和房颤。本文基于当前文献对兰地洛尔在重症监护患者心率控制方面进行综述并给出观点。

相似文献

1
Landiolol for managing atrial fibrillation in intensive care.兰地洛尔用于重症监护中房颤的管理。
Eur Heart J Suppl. 2018 Jan;20(Suppl A):A15-A18. doi: 10.1093/eurheartj/sux039. Epub 2018 Jan 8.
2
An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation.超短效β1选择性拮抗剂兰地洛尔在心房颤动中的药代动力学和药效学概述
Pharmaceutics. 2024 Apr 8;16(4):517. doi: 10.3390/pharmaceutics16040517.
3
Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial.兰地洛尔治疗脓毒症相关快速性心律失常的疗效和安全性（J-Land 3S）：一项多中心、开放标签、随机对照试验。
Lancet Respir Med. 2020 Sep;8(9):863-872. doi: 10.1016/S2213-2600(20)30037-0. Epub 2020 Mar 31.
4
Landiolol for managing post-operative atrial fibrillation.兰地洛尔用于治疗术后房颤。
Eur Heart J Suppl. 2018 Jan;20(Suppl A):A10-A14. doi: 10.1093/eurheartj/sux036. Epub 2018 Jan 8.
5
Landiolol for Treatment of New-Onset Atrial Fibrillation in Critical Care: A Systematic Review.在重症监护中使用兰地洛尔治疗新发房颤：一项系统评价
J Clin Med. 2024 May 17;13(10):2951. doi: 10.3390/jcm13102951.
6
Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis.兰地洛尔，一种超短效β1受体阻滞剂，可用于治疗脓毒症中的室上性快速心律失常。
World J Crit Care Med. 2015 Aug 4;4(3):251-7. doi: 10.5492/wjccm.v4.i3.251.
7
Evaluating the Therapeutic Efficacy and Safety of Landiolol Hydrochloride for Management of Arrhythmia in Critical Settings: Review of the Literature.评估盐酸兰地洛尔在危急情况下治疗心律失常的疗效和安全性：文献综述
Vasc Health Risk Manag. 2020 Apr 3;16:111-123. doi: 10.2147/VHRM.S210561. eCollection 2020.
8
Novel rate control strategy with landiolol in patients with cardiac dysfunction and atrial fibrillation.地尔硫䓬在伴有心功能障碍的心房颤动患者中的新型心率控制策略。
ESC Heart Fail. 2020 Oct;7(5):2208-2213. doi: 10.1002/ehf2.12879. Epub 2020 Jul 14.
9
Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction.兰地洛尔用于心功能不全患者房颤的心率控制管理。
Eur Heart J Suppl. 2018 Jan;20(Suppl A):A19-A24. doi: 10.1093/eurheartj/sux035. Epub 2018 Jan 8.
10
Safety and efficacy of landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery in patients with left ventricular dysfunction: Prevention of Atrial Fibrillation After Cardiac Surgery With Landiolol Hydrochloride for Left Ventricular Dysfunction (PLATON) trial.盐酸拉贝洛尔预防左心功能障碍患者心脏手术后心房颤动的安全性和有效性：盐酸拉贝洛尔预防左心室功能障碍心脏手术后心房颤动（PLATON）试验。
J Thorac Cardiovasc Surg. 2015 Oct;150(4):957-64. doi: 10.1016/j.jtcvs.2015.07.003. Epub 2015 Jul 10.

引用本文的文献

1
Mortality in septic patients treated with short-acting betablockers: a comprehensive meta-analysis of randomized controlled trials.短作用β受体阻滞剂治疗脓毒症患者的死亡率：随机对照试验的综合荟萃分析。
Crit Care. 2024 Nov 27;28(1):392. doi: 10.1186/s13054-024-05174-w.
2
The Impact of Chronic Oral Beta-Blocker Intake on Intravenous Bolus Landiolol Response in Hospitalized Intensive Care Patients with Sudden-Onset Supraventricular Tachycardia-A Post Hoc Analysis of a Cross-Sectional Trial.慢性口服β受体阻滞剂对突发室上性心动过速的住院重症监护患者静脉推注兰地洛尔反应的影响——一项横断面试验的事后分析
Pharmaceutics. 2024 Jun 20;16(6):839. doi: 10.3390/pharmaceutics16060839.
3
An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation.超短效β1选择性拮抗剂兰地洛尔在心房颤动中的药代动力学和药效学概述
Pharmaceutics. 2024 Apr 8;16(4):517. doi: 10.3390/pharmaceutics16040517.
4
Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care-A Retrospective Cross-Sectional Study.推注剂量兰地洛尔在重症监护中的血流动力学和节律学效应——一项回顾性横断面研究
Pharmaceuticals (Basel). 2023 Jan 17;16(2):134. doi: 10.3390/ph16020134.
5
Relationship between red blood cell distribution width-to-albumin ratio and outcome of septic patients with atrial fibrillation: a retrospective cohort study.红细胞分布宽度与白蛋白比值与合并心房颤动脓毒症患者预后的关系：一项回顾性队列研究。
BMC Cardiovasc Disord. 2022 Dec 9;22(1):538. doi: 10.1186/s12872-022-02975-1.
6
Landiolol for refractory tachyarrhythmias in the intensive care unit: case reports.兰地洛尔用于重症监护病房难治性快速性心律失常：病例报告
Eur Heart J Suppl. 2022 Jun 13;24(Suppl D):D43-D49. doi: 10.1093/eurheartjsupp/suac026. eCollection 2022 Jun.
7
Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review.重症监护病房中新发心房颤动患者的治疗策略：系统范围综述。
Crit Care. 2021 Jul 21;25(1):257. doi: 10.1186/s13054-021-03684-5.
8
Effect of landiolol on sex-related transcriptomic changes in the myocardium during sepsis.兰地洛尔对脓毒症期间心肌中与性别相关的转录组变化的影响。
Intensive Care Med Exp. 2019 Aug 19;7(1):50. doi: 10.1186/s40635-019-0263-0.
9
Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting.兰地洛尔：药理学及其在紧急情况下控制房颤心率方面的应用。
Eur Heart J Suppl. 2018 Jan;20(Suppl A):A1-A3. doi: 10.1093/eurheartj/sux037. Epub 2018 Jan 8.

本文引用的文献

1
Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction.兰地洛尔用于心功能不全患者房颤的心率控制管理。
Eur Heart J Suppl. 2018 Jan;20(Suppl A):A19-A24. doi: 10.1093/eurheartj/sux035. Epub 2018 Jan 8.
2
Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days.在严重脓毒症和脓毒性休克的急性期持续使用慢性β受体阻滞剂与 90 天内死亡率降低相关。
Br J Anaesth. 2017 Oct 1;119(4):616-625. doi: 10.1093/bja/aex231.
3
Neutrophil stunning by metoprolol reduces infarct size.美托洛尔使中性粒细胞“失活”，减少梗死面积。
Nat Commun. 2017 Apr 18;8:14780. doi: 10.1038/ncomms14780.
4
New-Onset Atrial Fibrillation in the Critically Ill.危重症患者新发房颤
Crit Care Med. 2017 May;45(5):790-797. doi: 10.1097/CCM.0000000000002325.
5
Prognostic impact of restored sinus rhythm in patients with sepsis and new-onset atrial fibrillation.脓毒症合并新发房颤患者恢复窦性心律的预后影响
Crit Care. 2016 Nov 18;20(1):373. doi: 10.1186/s13054-016-1548-2.
6
Landiolol hydrochloride ameliorates acute lung injury in a rat model of early sepsis through the suppression of elevated levels of pulmonary endothelin-1.盐酸兰地洛尔通过抑制肺内皮素-1水平升高改善早期脓毒症大鼠模型的急性肺损伤。
Life Sci. 2016 Dec 1;166:27-33. doi: 10.1016/j.lfs.2016.10.010. Epub 2016 Oct 11.
7
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动管理指南。
Europace. 2016 Nov;18(11):1609-1678. doi: 10.1093/europace/euw295. Epub 2016 Aug 27.
8
Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation in Critically Ill Patients with Sepsis. A Cohort Study.严重脓毒症患者新发心房颤动的发生率、预测因素和结局：一项队列研究。
Am J Respir Crit Care Med. 2017 Jan 15;195(2):205-211. doi: 10.1164/rccm.201603-0618OC.
9
Atrial Fibrillation on Intensive Care Unit Admission Independently Increases the Risk of Weaning Failure in Nonheart Failure Mechanically Ventilated Patients in a Medical Intensive Care Unit: A Retrospective Case-Control Study.重症监护病房入院时的心房颤动独立增加了内科重症监护病房非心力衰竭机械通气患者撤机失败的风险：一项回顾性病例对照研究。
Medicine (Baltimore). 2016 May;95(20):e3744. doi: 10.1097/MD.0000000000003744.
10
Incidence, Risk Factors and Outcomes of New Onset Supraventricular Arrhythmias in African American Patients with Severe Sepsis.非裔美国严重脓毒症患者新发室上性心律失常的发生率、风险因素和结局。
Ethn Dis. 2016 Apr 21;26(2):205-12. doi: 10.18865/ed.26.2.205.